- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06205875
High Versus Low Dose Serratus Anterior Plane Block After Minimally Invasive Valve Surgery.
High Versus Low Dose Serratus Anterior Plane Block After Minimally Invasive Valve Surgery: a Double-blinded Randomized Controlled Trial.
Study Overview
Status
Conditions
Detailed Description
During the last two decades, cardiac surgical techniques have changed dramatically. Evidence for good short and long-term outcomes after endovascular and minimally invasive procedures is rising. This shift made it possible to avoid sternotomy and thus facilitating earlier patient recovery without compromising safety. Therefore, enhanced recovery after surgery (ERAS) protocols have been implemented to aim for early extubation and ambulation. While policies for early extubation and discharge from the hospital have been implemented, the analgesic regimen has not been modified. Opioids remain the standard treatment in the postoperative setting after cardiac surgery despite known side effects such as nausea, constipation and the risk of addiction. Neuraxial anaesthesia techniques, which require fewer opioids in cardiac surgery, have been studied and validated but not yet implemented.
In 2013, the serratus anterior plane (SAP) block was described as a pain relief option for chest surgery. This anaesthesia technique injects local anaesthetics under the serratus muscle and between the latissimus dorsi and serratus anterior using ultrasound. Successful pain relief with this SAP block has been reported in thoracotomy, chest surgery, and rib fractures. In our previous study, we demonstrated a 40% reduction in morphine consumption during the first 24 hours after total endoscopic aortic valve replacement with an SAP block compared to a control group without an SAP block. Lower pain scores were also observed in the SAP group
As such, in this proposed study, we aim to optimise the intensity of the Serratus anterior plane block (SAPB) to decrease opioid requirements further and to encounter more favourable secondary clinical outcome parameters. One strategy to increase the duration of action of plane blocks is injecting higher doses of local anaesthetics. A meta-analysis by De Oliveira et al. on transabdominal plane (TAP)-blocks for abdominal surgery showed a correlation between the local anaesthetic dose and the late block effect, impacting both pain scores and opioid consumption. In a randomised controlled trial by Suresh, a TAP block with bupivacaine 1.25 mcg/kg was compared to a TAP block with bupivacaine 2.5 mcg/kg, revealing a longer duration of analgesia and a lower need for additional analgesics up to 24 hours post-surgery. Moreover, loading doses up to 2mg/kg body weight are recommended for truncal blocks in general, but the mean injected dose in our intervention group was 1.25mg/kg, considering a mean patient body weight of 79.2kg. Notably, a pharmacokinetic study by Maximos and colleagues on an adrenalised bupivacaine mixture after pectointercostal fascial plane block (PIFB) after cardiac surgery showed that, despite injecting 2mcg/kg adrenalised bupivacain, both total and free arterial serum bupivacaine levels were 10-20 times lower than levels associated with neurologic or cardiovascular toxicity in the literature.
In conclusion, we are convinced we can safely improve the late effects of our SAPB compared to our first study by increasing the dose of the local anesthetic injectate.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Björn Stessel, Dr
- Phone Number: 003211222107
- Email: bjorn.stessel@jessazh.be
Study Contact Backup
- Name: Ina Callebout, PhD
- Phone Number: 003211339848
- Email: ina.callebaut@jessazh.be
Study Locations
-
-
Limburg
-
Hasselt, Limburg, Belgium, 3500
- Recruiting
- Jessa hospital
-
Contact:
- Björn Stessel, Dr.
- Phone Number: 003211339856
- Email: bjorn.stessel@jessazh.be
-
Contact:
- Ina Callebaut, PhD
- Phone Number: 003211339848
- Email: ina.callebaut@jessazh.be
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Scheduled for elective aortic valve surgery or elective mitral valve surgery via right anterolateral thoracotomy
- Adult patients (minimally 18 years old)
- Bodyweight > 50kg
- EuroScore ii < 3%
Exclusion Criteria:
- Refusal to participate
- Inability to communicate due to language or neurologic barriers
- Inability to control and self-administer opioids with PCIA or to comprehend the NRS pain score due to confusion or learning difficulties
- Chronic use of opioids
- Chronic use of analgesic antidepressants and/or antiepileptics
- Use of prohibited medication which possibly interacts with bupivacaine-epinephrine or opioids (mexiletine, ketoconazole, theophylline, IMAO, Digitalis and cimetidine)
- History of major trauma or surgery to right chest wall
- History of chronic pain at right chest wall
- Allergy to opioids and/or local anesthetics
- Allergy to paracetamol
- Class 3 obesity (BMI 40 or more)
- Pregnancy
- Intraoperative events compromising early postoperative recovery (aortic dissection, systolic anterior motion of the mitral valve, cardiac tamponade, brady-arrhytmias requiring external pacing,...)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention group
Patients in the intervention group will receive a mixture of high-dose local anesthetic and epinephrine administered via a serratus anterior plane block.
|
A patient controlled intravenous analgesia system (Bodyguard 595 Colorvision®) with morphine (Sterop®) using following settings: bolus 1.5 mg and lockout interval 7 min with maximal dose of 30mg per 4 hours.
Other Names:
The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment).
Under continuous ultrasound guidance, 3/4th of the bupivacaine 0.25% plus epinephrine solution will be injected in the deep compartment.
After the deep component of the serratus anterior plane block is completed, the needle will be withdrawn to the subcutaneous tissues.
The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles.
The remainder quarter of the bupivacaine 0.25% plus epinephrine solution will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound.
In total a dose of 2.4mg/kg patient ideal body weight will be administered.
There is a maximal dose of 200 mg adrenalized bupivacaine for patients with an ideal body weight of 83 kg or more.
|
Active Comparator: Control group
Patients in the control group will receive a serratus anterior plane block with a low dose local anesthetic (based upon our primary trial).
|
A patient controlled intravenous analgesia system (Bodyguard 595 Colorvision®) with morphine (Sterop®) using following settings: bolus 1.5 mg and lockout interval 7 min with maximal dose of 30mg per 4 hours.
Other Names:
The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment).
Under continuous ultrasound guidance, 3/4th of the bupivacaine 0.25% will be injected in the deep compartment.
After the deep component of the serratus anterior plane block is completed, the needle will be withdrawn to the subcutaneous tissues.
The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles.
The remainder quarter of the bupivacaine 0.25% will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative opioid consumption by patient-controlled intravenous analgesia (PCIA)
Time Frame: 24 hours after block placement
|
Morphine consumption will be directly read from the PCIA-system after 24 hours
|
24 hours after block placement
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to extubation
Time Frame: Throughout study completion, an average of 7 days
|
Time from arrival to the ICU until extubation in minutes.
|
Throughout study completion, an average of 7 days
|
ICU length of stay
Time Frame: Until postoperative day 7
|
Time from arrival to the ICU until meeting discharge criteria to the ward in postoperative hours.
|
Until postoperative day 7
|
Pneumonia
Time Frame: Until postoperative day 7
|
Defined as empirical antibiotic therapy for suspicion of pneumonia during hospital stay, in number of patients.
|
Until postoperative day 7
|
Opioid consumption during predetermined time intervals after surgery
Time Frame: Every 4 hours until 24 hours after placement of the SAP block
|
Morphine consumption will be directly read from PCIA-system at predetermined time intervals after performing the SAP block.
|
Every 4 hours until 24 hours after placement of the SAP block
|
Opioid free patients first 24 postoperative hours
Time Frame: First 24 hours
|
Number of patients that do not require any additional opioids within the first 24 hours after block placement.
|
First 24 hours
|
Postoperative pain score in rest and on deep respiration
Time Frame: 4, 8, 12 and 24 hours after performing the SAP block and at postoperative day 7.
|
The postoperative pain in rest, as well as with deep respiration on the surgical site, is evaluated based on an 11-point numeric scale (NRS) where 0 = no pain and 10 = worst pain ever.
|
4, 8, 12 and 24 hours after performing the SAP block and at postoperative day 7.
|
Overall patient Satisfaction with analgesic therapy
Time Frame: 24 hours after performing the SAP block at postoperative day 1.
|
Overall patient satisfaction with analgesic therapy will be assessed with an 11-point NRS scale (where 0 = not satisfied at all and 10 = extremely satisfied)
|
24 hours after performing the SAP block at postoperative day 1.
|
Time to first mobilization
Time Frame: Intended at 6 hours after surgery
|
Time from arrival to the ICU until first mobilization.
|
Intended at 6 hours after surgery
|
Postoperative nausea and vomiting (PONV)
Time Frame: 24 hours after performing the SAP block at postoperative day 1
|
The simplified PONV impact scale will be used to asses PONV.
Clinically important PONV will be defined as a score of 5 or more.
|
24 hours after performing the SAP block at postoperative day 1
|
Constipation
Time Frame: Until postoperative day 7
|
Time to first defecation (postoperative days) or need for laxatives during hospital stay (number of patients)
|
Until postoperative day 7
|
Hospital length of stay
Time Frame: Throughout study completion, an average of 7 days
|
Time to discharge out of the hospital in postoperative days (day of surgery = day 0)
|
Throughout study completion, an average of 7 days
|
Quality of recovery
Time Frame: At postoperative day 2 and 7
|
Quality of recovery will be assessed with Quality of Life questionnaires: EuroQol*5D (EQ5D) and short form health survey (SF-36).
|
At postoperative day 2 and 7
|
Bupivacaine dosage
Time Frame: at 30minutes as well as at 1, 2, 4 and 8 hours after block placement
|
In the first 36 study patients, arterial blood samples will be taken to calculate the dosage of total and free plasma bupivacaine levels.
For each patient 5 samples will be collected, with a total amount of 50 ml blood per patient.
|
at 30minutes as well as at 1, 2, 4 and 8 hours after block placement
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Postoperative Complications
- Pain
- Neurologic Manifestations
- Heart Diseases
- Pain, Postoperative
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Opioid
- Narcotics
- Morphine
Other Study ID Numbers
- f/2023/119
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Analgesia
-
Mansoura UniversityNot yet recruiting
-
Southeast University, ChinaRecruiting
-
Medical University of South CarolinaRecruiting
-
Southeast University, ChinaRecruiting
-
Huazhong University of Science and TechnologyRecruiting
-
Mansoura UniversityCompleted
-
University of FloridaMdoloris Medical SystemsCompletedAnalgesiaUnited States
-
Mansoura UniversityCompleted
-
Cessatech A/SCompleted
-
Kalyra Pharmaceuticals, Inc.United States Department of Defense; PRA Health SciencesTerminated
Clinical Trials on PCIA with morphine
-
Second Affiliated Hospital, School of Medicine,...Completed
-
Cui XuleiCompletedAnalgesia | Hepatectomy | Paravertebral Block | Postoperative RecoveryChina
-
Jessa HospitalCompletedAnalgesia | Surgery | Cardiac DiseaseBelgium
-
Shanghai Zhongshan HospitalCompletedPain, Postoperative | Anesthesia | ThoracotomyChina
-
Peking University Third HospitalCompleted
-
Rambam Health Care CampusUnknownRespiratory DepressionIsrael
-
Rijnstate HospitalCompletedTotal Hip Replacement
-
IRCCS Policlinico S. MatteoUnknownChronic Pain | Acute Pain | Mastectomy | Wound InfusionItaly
-
Vishal UppalMaisonneuve-Rosemont Hospital; IWK Health CentreUnknown
-
American University of Beirut Medical CenterCompletedAnesthesia | Total Knee ArthroplastyLebanon